Bengaluru: Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help ...

Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...

Earlier on Wednesday, Laekna, “a global biotech company focused on novel drug development for metabolic and cancer diseases,” accoding to its ...

LAEKNA-B (02105.HK) announced that it intends to place a total of 17.636 million shares of the company, equivalent to about 4 ...

Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...

Eli Lilly (LLY) partners with Laekna Therapeutics to develop an obesity therapy that avoids muscle loss. Read more here.

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...

Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...

LAEKNA-B (02105.HK) opened 0.94% lower today (20th) but managed to make a rebound, peaking at $14.54 with an uptick of 37%.